Posted by Michael Wonder on 22 Jul 2021
Bayer’s new symptomatic chronic heart failure treatment Verquvo (vericiguat) approved in EU
21 July 2021 - Approved for adult patients with reduced ejection fraction who are stabilised after a recent decompensation event requiring intravenous therapy.
The European Commission has granted marketing authorisation in the European Union for vericiguat under the brand name Verquvo.
